SK-BR-3-luc Orthotopic Mouse Model Service for Breast Cancer

The SK-BR-3-luc orthotopic mouse model represents a refined in vivo platform for HER2-positive breast cancer, combining the aggressive molecular profile of SK-BR-3 cells with constitutive luciferase expression for sensitive, real-time tumor tracking. Alfa Cytology delivers this advanced orthotopic xenograft service with rigorous quality control, enabling researchers to monitor tumor progression, metastatic dissemination, and therapeutic response through non-invasive bioluminescence imaging in a mammary fat pad microenvironment that closely recapitulates human disease pathology.

Overview of SK-BR-3-luc Orthotopic Mouse Model for Breast Cancer

The SK-BR-3 cell line was originally isolated in 1970 from the pleural effusion of a 43-year-old female patient with metastatic breast adenocarcinoma at Memorial Sloan-Kettering Cancer Center. Genetically, SK-BR-3 is classified within the HER2-enriched molecular subtype, characterized by amplification and robust overexpression of the ERBB2 (HER2) oncogene, while remaining negative for estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR). The cells harbor TP53 mutations and exhibit a near-triploid karyotype with approximately 61 chromosomes. When engineered to stably express firefly luciferase, the resulting SK-BR-3-luc reporter line enables constitutive bioluminescent signal emission, permitting quantitative, longitudinal assessment of tumor burden in vivo without sacrificing experimental animals at each time point. This optical reporter integration transforms the model into a dynamic system for studying HER2-driven oncogenesis, therapeutic resistance, and metastatic cascade in real time.

Fig 1. Effects of CK1δ/CK1ε inhibitors on growth and establishment of MDA-MB-231-luc tumors monitored by luminescence intensity over time. (Rosenberg, Laura H., et al., 2015)

Orthotopic implantation of SK-BR-3-luc cells into the mammary fat pad of immunodeficient mice—most commonly athymic nude or NOD/SCID strains—establishes a tumor microenvironment that preserves critical stromal interactions, vascular architecture, and immune contexture relevant to human breast carcinoma. Unlike subcutaneous models, the orthotopic approach fosters organ-specific tropism, supports spontaneous metastasis to regional lymph nodes and distant organs, and provides a more faithful representation of clinical drug pharmacokinetics and tumor response dynamics. The luciferase reporter further allows researchers to distinguish between primary tumor regression and occult metastatic outgrowth, a distinction essential for evaluating the true efficacy of HER2-targeted agents, antibody-drug conjugates, and combination regimens in preclinical settings.

Cell Line Information: SK-BR-3-luc

The SK-BR-3-luc reporter cell line is a genetically engineered derivative of the parental SK-BR-3 human breast adenocarcinoma line. Below is a comprehensive summary of its origin, molecular characteristics, culture parameters, and quality specifications:

Our Services

Alfa Cytology provides end-to-end SK-BR-3-luc orthotopic model services encompassing cell line authentication, luciferase expression validation, surgical implantation, longitudinal bioluminescence imaging, and comprehensive histopathological endpoint analysis. Our technical team ensures stringent mycoplasma and pathogen screening, optimized Matrigel ratios for engraftment consistency, and calibrated imaging protocols that yield reproducible photon flux quantification across cohorts. Whether your program requires single-agent efficacy assessment or complex combination studies with pharmacokinetic sampling, we tailor each study design to your specific therapeutic hypothesis and regulatory documentation needs.

Workflow of SK-BR-3-luc Orthotopic Mouse Model Construction

Construction of the SK-BR-3-luc orthotopic model follows a standardized yet adaptable protocol designed to maximize engraftment rates, minimize surgical morbidity, and ensure bioluminescence signal fidelity throughout the study duration. The process integrates cell culture quality assurance, sterile surgical technique, and rigorous in vivo imaging calibration. Below are the essential steps:

1. Cell Line Expansion and Authentication: SK-BR-3-luc cells are expanded from cryopreserved master stocks under antibiotic-free conditions. Each batch undergoes STR profiling to confirm identity, mycoplasma PCR to exclude contamination, and luciferase activity assay in vitro to verify reporter expression levels prior to implantation.
2. Pre-Implantation Cell Preparation: On the day of surgery, cells are harvested at logarithmic growth phase using gentle trypsinization, washed twice in sterile PBS, and resuspended at a concentration of 1–5 x 10⁷ cells/mL in ice-cold PBS or PBS/Matrigel (1:1 v/v) mixture. Cell viability is confirmed by trypan blue exclusion (>95% viable).
3. Animal Preparation and Anesthesia: Immunodeficient recipient mice (athymic nude or NOD/SCID, 6–8 weeks old, female) are acclimated for one week. On the procedure day, mice receive general anesthesia via inhalational isoflurane (2–3% in oxygen) or injectable ketamine/xylazine cocktail, with body temperature maintained on a heated surgical pad.
4. Orthotopic Mammary Fat Pad Injection: A small skin incision is made over the left or right inguinal mammary fat pad (#4 or #5). A 28-gauge insulin syringe is used to deliver 50–100 μL of the cell suspension directly into the fat pad stroma. The needle is advanced parallel to the body wall to avoid puncturing underlying musculature, then slowly withdrawn to minimize reflux. The skin is closed with surgical adhesive or wound clips.
5. Post-Operative Monitoring and Recovery: Mice are placed in a warmed recovery chamber and monitored until fully ambulatory. Analgesia (buprenorphine 0.05–0.1 mg/kg, s.c.) is administered per institutional guidelines. Animals are inspected daily for wound integrity, body weight, and signs of distress for 7 days post-surgery.
6. Baseline and Longitudinal Bioluminescence Imaging: Starting 7–10 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Baseline signal is recorded, and subsequent imaging sessions (typically weekly or bi-weekly) track tumor establishment, exponential growth phase, and response to intervention. Regions of interest (ROI) are drawn to quantify total photon flux (photons/sec).
7. Therapeutic Intervention and Pharmacodynamic Sampling: Upon reaching a predefined tumor burden (e.g., 1–5 x 10⁶ photons/sec or palpable tumor ~50–100 mm³), mice are randomized into treatment cohorts. Test articles are administered according to the study protocol (oral gavage, intravenous, intraperitoneal, or subcutaneous routes). Tumor dimensions and body weights are recorded twice weekly. Blood, serum, or plasma samples may be collected at designated intervals for pharmacokinetic analysis.
8. Endpoint Analysis and Histopathological Evaluation: At study termination, mice are euthanized humanely. Primary tumors are excised, weighed, and photographed. Tumors and suspected metastatic tissues (lung, liver, lymph nodes, bone) are fixed in 10% neutral buffered formalin, paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E). Immunohistochemistry for Ki-67, cleaved caspase-3, CD31, and HER2 is performed to assess proliferation, apoptosis, angiogenesis, and target engagement, respectively.

Fig 2. SK-BR-3-luc Orthotopic Mouse Model construction workflow.

Case Study-SK-BR-3-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, SK-BR-3-luc cells were orthotopically implanted into the mammary fat pads of female NOD/SCID mice to evaluate a novel HER2-targeting small molecule inhibitor in combination with standard-of-care trastuzumab. Tumors established robust bioluminescence signal within 10–14 days, with exponential growth observed between weeks 3 and 5. Mice were randomized at a mean photon flux of approximately 2 x 10^⁶ photons/sec and dosed for 3 weeks. The combination arm demonstrated significant tumor growth inhibition compared to vehicle and monotherapy controls, as evidenced by reduced photon flux, decreased tumor weight at necropsy, and diminished Ki-67 staining. Notably, bioluminescence imaging revealed differential patterns of signal distribution between treatment groups, suggesting that the combination regimen not only suppressed primary tumor expansion but also altered metastatic seeding dynamics to regional lymph nodes. These findings illustrate the utility of the SK-BR-3-luc orthotopic platform for capturing both local tumor control and systemic anti-cancer activity in a single in vivo experiment.

Why Choose Alfa Cytology?

Selecting the right CRO partner for your HER2-positive breast cancer program directly impacts the translational value of your preclinical data. Alfa Cytology differentiates its SK-BR-3-luc orthotopic service through technical depth, operational flexibility, and unwavering commitment to data integrity:

• We maintain authenticated, low-passage SK-BR-3-luc master cell banks with documented STR profiles and routine mycoplasma surveillance, eliminating genetic drift and contamination risks that compromise study reproducibility.
• Our surgical team performs orthotopic implantations with high engraftment success rates, utilizing refined needle placement techniques that preserve mammary fat pad architecture and minimize perioperative mortality.
• Bioluminescence imaging is conducted on calibrated IVIS platforms with standardized D-luciferin dosing and ROI analysis protocols, ensuring quantitative comparability across studies, sites, and time points.
• Study designs are fully customizable—we accommodate variable cell inoculum sizes, co-implantation with human fibroblasts or immune components, and complex dosing schedules including intermittent or dose-escalation regimens.
• All endpoint analyses include digital pathology with whole-slide scanning, enabling remote peer review, AI-assisted quantification, and seamless integration with your internal data management systems.
• We provide comprehensive study reports with raw data packages, statistical analysis plans, and GLP-compliant documentation upon request, supporting seamless transition to IND-enabling toxicology studies or regulatory submissions.

Contact Us

If you are advancing a HER2-targeted therapeutic pipeline and require a preclinical orthotopic model that captures both primary tumor biology and metastatic potential with real-time optical tracking, we encourage you to reach out to us to discuss your specific program requirements. The team at Alfa Cytology is prepared to design a tailored SK-BR-3-luc orthotopic study protocol aligned with your pharmacological objectives, timeline, and budget. Contact us today to receive a detailed proposal and project timeline, and let us help accelerate your breast cancer research from bench to bedside.

For research use only. Not intended for any clinical use.